ctDNA is not a simple positive/negative binary test. Like PSA in prostate cancer, the quantitative level of ctDNA correlates with patient outcomes. Higher levels indicate a worse prognosis and a faster time to relapse, allowing for more nuanced risk stratification beyond a simple presence or absence of the biomarker.

While promising, circulating tumor DNA (ctDNA) from plasma is not yet ready for guiding local treatment decisions in bladder cancer. Data from studies like RETAIN show it is insufficient for identifying patients with residual disease confined to the bladder, limiting its utility in bladder-sparing protocols.

Data from trials like Niagara suggests a powerful new paradigm for assessing treatment success. Combining urine tumor DNA (uTDNA) for local disease and circulating tumor DNA (ctDNA) for systemic relapse offers a more dynamic view than traditional pathology and is poised to become the superior surrogate endpoint in bladder cancer trials.

Circulating tumor DNA (ctDNA) is a powerful tool in bladder cancer. A positive result post-surgery is a strong indicator for initiating adjuvant therapy. However, a negative result does not guarantee a cure, as a notable percentage of these patients still relapse, making clinicians cautious about withholding treatment based on a single negative test.

Circulating tumor DNA is a powerful tool for detecting systemic minimal residual disease but is not sensitive enough for local, non-muscle invasive recurrences. This limitation means traditional surveillance like cystoscopy remains indispensable, as a negative ctDNA test can provide a false sense of security about local control.

Circulating tumor DNA (ctDNA) is a powerful biomarker for identifying high-risk bladder cancer patients. However, its imperfection presents a new clinical dilemma: with a ~12% relapse rate even in ctDNA-negative patients, clinicians must decide whether to withhold adjuvant therapy and accept that risk, or overtreat the 88% who are likely cured.

The future of bladder cancer surveillance may involve using two types of liquid biopsies in tandem. A patient who is utDNA-positive but ctDNA-negative likely has a local, primary bladder issue. Conversely, a utDNA-negative but ctDNA-positive result suggests the cancer has already spread systemically, providing crucial information for treatment planning.

While circulating tumor DNA (ctDNA) is a powerful prognostic marker, it is not yet part of the formal "clinical complete response" definition for bladder-sparing trials. Experts lack data on its ability to predict the superficial, non-muscle invasive relapses common in this setting.

Professor Powles predicts that urinary tumor DNA (utDNA) will become the key biomarker for detecting local relapse in bladder-sparing strategies. He notes that blood-based ctDNA is poor at identifying non-muscle invasive disease, creating a clear and necessary role for utDNA to assess local risk and guide interventions more accurately.